Co-Diagnostics sets Sept. 16 investor briefing

Q: What did CODX announce in its September 16, 2026 Form 8-K?

Co-Diagnostics, Inc. announced that on September 16, 2026 it will host an investor and analyst presentation covering its collaboration with ReadyGo Diagnostics Ltd., the Co-Dx PCR platform, related development activities, manufacturing initiatives, and operations in India.

Q: What topics will Co-Diagnostics, Inc. (CODX) cover in the new investor presentation?

The presentation will address collaboration with ReadyGo Diagnostics Ltd., the company’s Co-Dx PCR platform and related development, as well as manufacturing initiatives and operations in India, according to Co-Diagnostics, Inc.

Q: What is Exhibit 99.1 referenced by CODX in the 8-K?

Exhibit 99.1 is an Investor and Analyst Presentation dated September 16, 2026 that Co-Diagnostics, Inc. will use for its investor and analyst event. It is furnished as part of a Regulation FD disclosure for informational purposes.

Co-Diagnostics, Inc. (CODX) reports that on September 16, 2026 it will host an investor and analyst presentation.

Available on EDGAR 09/16/2026 - 10:30 AM EDT Accepted by SEC EDGAR 09/16/2026 - 10:30 AM EDT

Filing Impact

(High)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Co-Diagnostics, Inc. (CODX) reports that on September 16, 2026 it will host an investor and analyst presentation. The presentation will cover the company’s collaboration with ReadyGo Diagnostics Ltd., its Co-Dx PCR platform and related development activities, manufacturing initiatives, and operations in India.

The slide deck for this event is provided as an Investor and Analyst Presentation dated September 16, 2026 and furnished as Exhibit 99.1 under a Regulation FD disclosure, meaning it is supplied for informational purposes and is not treated as filed under the Exchange Act.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Presentation date: September 16, 2026 Exhibit 99.1: Investor and Analyst Presentation dated September 16, 2026 Trading symbol: CODX

3 metrics

Presentation date September 16, 2026 Date of Co-Diagnostics, Inc. investor and analyst presentation

Exhibit 99.1 Investor and Analyst Presentation dated September 16, 2026 Furnished under Regulation FD disclosure

Trading symbol CODX Common Stock listed on The Nasdaq Capital Market

Key Terms

Regulation FD, Investor and Analyst Presentation, Inline XBRL, Emerging growth company

4 terms

Regulation FD regulatory

"Item 7.01 Regulation FD Disclosure"

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

Investor and Analyst Presentation financial

"Investor and Analyst Presentation dated September 16, 2026"

Inline XBRL technical

"Cover Page Interactive Data File (embedded within the Inline XBRL document)"

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CODX announce in its September 16, 2026 Form 8-K?

Co-Diagnostics, Inc. announced that on September 16, 2026 it will host an investor and analyst presentation covering its collaboration with ReadyGo Diagnostics Ltd., the Co-Dx PCR platform, related development activities, manufacturing initiatives, and operations in India.

What topics will Co-Diagnostics, Inc. (CODX) cover in the new investor presentation?

The presentation will address collaboration with ReadyGo Diagnostics Ltd., the company’s Co-Dx PCR platform and related development, as well as manufacturing initiatives and operations in India, according to Co-Diagnostics, Inc.

What is Exhibit 99.1 referenced by CODX in the 8-K?

Exhibit 99.1 is an Investor and Analyst Presentation dated September 16, 2026 that Co-Diagnostics, Inc. will use for its investor and analyst event. It is furnished as part of a Regulation FD disclosure for informational purposes.

Is the Co-Diagnostics, Inc. (CODX) investor presentation considered filed under the Exchange Act?

No. Co-Diagnostics, Inc. states that the information in the Regulation FD item, including Exhibit 99.1, is being furnished and is not deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to its liabilities.

Does the CODX 8-K include any new financial statements or earnings data?

No. The Co-Diagnostics, Inc. Form 8-K describes an investor and analyst presentation and identifies related exhibits. It does not present financial statements or earnings data within the described items.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 16, 2026

CO-DIAGNOSTICS, INC.

(Exact name of registrant as specified in its charter)

Utah

001-38148

46-2609363

(State or other jurisdiction

of incorporation)

(Commission
File Number)

(IRS Employer

Identification No. )

2401 S. Foothill Drive, Suite D, Salt Lake City Utah 84109

(Address of principal executive offices) (Zip Code)

(801) 438-1036

Registrant’s telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		CODX		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 16, 2026, Co-Diagnostics, Inc. (the “Company”) will host an investor and analyst presentation regarding, among other matters, the Company’s collaboration with ReadyGo Diagnostics Ltd., the Company’s Co-Dx PCR platform and related development activities, manufacturing initiatives, and operations in India.

A copy of the presentation materials to be used in connection with the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.:		Description:
99.1		Investor and Analyst Presentation dated September 16, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.